• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

High prevalence of benign prostatic hypertrophy in the community.

作者信息

Garraway W M, Collins G N, Lee R J

机构信息

Department of Public Health Sciences, Edinburgh University, UK.

出版信息

Lancet. 1991 Aug 24;338(8765):469-71. doi: 10.1016/0140-6736(91)90543-x.

DOI:10.1016/0140-6736(91)90543-x
PMID:1714529
Abstract

There is a strong suspicion among urologists that the prevalence of benign prostatic hyperplasia is higher than has been reported in clinical retrospective and necropsy studies. To find out the prevalence in one community all men aged 40-79 years registered with a group general practice were invited to complete a urinary symptom questionnaire and to undergo uroflowmetry. 705 men (77% of those eligible) participated. 214 men (84% of those invited) with signs and symptoms of prostatic dysfunction subsequently underwent transrectal ultrasonography (TRUS) for assessment of the volume (and by inference weight) of their prostates. The prevalence rate of benign prostatic hypertrophy (BPH), defined as enlargement of the prostate gland of equivalent weight greater than 20 g in the presence of symptoms of urinary dysfunction and/or a urinary peak flow rate less than 15 ml/s and without evidence of malignancy, was 253 (95% CI 221-285) per 1000 men in the community, rising from 138 per 1000 men aged 40-49 years to 430 per 1000 men aged 60-69 years. Thus apparently well men have a much higher frequency of BPH than was previously thought to be the case.

摘要

相似文献

1
High prevalence of benign prostatic hypertrophy in the community.
Lancet. 1991 Aug 24;338(8765):469-71. doi: 10.1016/0140-6736(91)90543-x.
2
Benign prostatic hyperplasia in an unselected community-based population: a survey of urinary symptoms, bothersomeness and prostatic enlargement.
Br J Urol. 1996 Feb;77(2):186-91. doi: 10.1046/j.1464-410x.1996.08593.x.
3
Prevalence of benign prostatic hyperplasia in Spanish men 40 years old or older.
J Urol. 1998 Mar;159(3):878-82. doi: 10.1097/00005392-199803000-00072.
4
Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men.既往未被认识的良性前列腺增生对中老年男性日常活动的影响。
Br J Gen Pract. 1993 Aug;43(373):318-21.
5
A study of benign prostatic hyperplasia--a challenge to British urology.良性前列腺增生症的研究——对英国泌尿外科的一项挑战。
Br J Urol. 1993 Jan;71(1):38-42. doi: 10.1111/j.1464-410x.1993.tb15877.x.
6
Consultation patterns in a community survey of men with benign prostatic hyperplasia.一项针对良性前列腺增生男性的社区调查中的咨询模式。
Br J Gen Pract. 1994 Nov;44(388):499-502.
7
Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.基于社区的健康老年男性人群中提示良性前列腺增生的下尿路症状的危险因素:克林彭研究
J Urol. 2009 Feb;181(2):710-6. doi: 10.1016/j.juro.2008.10.025. Epub 2008 Dec 16.
8
Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: a 15-year longitudinal community-based study.在日本男性中,良性前列腺增生症的治疗发生率和风险:一项长达 15 年的基于社区的纵向研究。
Int J Urol. 2013 Jan;20(1):100-6. doi: 10.1111/j.1442-2042.2012.03215.x. Epub 2012 Oct 29.
9
Urinary symptoms in the community: how bothersome are they?社区中的泌尿系统症状:它们有多困扰人?
Br J Urol. 1994 Nov;74(5):551-5. doi: 10.1111/j.1464-410x.1994.tb09182.x.
10
Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia.维生素D缺乏作为良性前列腺增生的潜在标志物
Urology. 2016 Nov;97:212-218. doi: 10.1016/j.urology.2016.03.070. Epub 2016 Jun 17.

引用本文的文献

1
TIAM1 drives prostatic branching phenotype and is a potential therapeutic target for benign prostatic hyperplasia.TIAM1驱动前列腺分支表型,是良性前列腺增生的一个潜在治疗靶点。
JCI Insight. 2025 May 20;10(12). doi: 10.1172/jci.insight.188062. eCollection 2025 Jun 23.
2
Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives.良性前列腺增生中的氧化应激:机制、临床相关性及治疗前景
Diseases. 2025 Feb 11;13(2):53. doi: 10.3390/diseases13020053.
3
Aging-Related Mitochondrial Dysfunction Is Associated With Fibrosis in Benign Prostatic Hyperplasia.
衰老相关的线粒体功能障碍与良性前列腺增生中的纤维化有关。
J Gerontol A Biol Sci Med Sci. 2024 Jun 1;79(6). doi: 10.1093/gerona/glad222.
4
The Efficacy of Cyclooxygenase-2 Inhibitors for the Male Treatment of Lower Urinary Tract Symptoms: A Systematic Review and Meta-Analysis.环氧化酶-2 抑制剂治疗男性下尿路症状的疗效:系统评价和荟萃分析。
Am J Mens Health. 2023 May-Jun;17(3):15579883231176667. doi: 10.1177/15579883231176667.
5
The method is feasible for beginners learning to perform holmium laser enucleation of the prostate.该方法对于刚开始学习进行钬激光前列腺剜除术的人来说是可行的。
Transl Androl Urol. 2023 Mar 31;12(3):477-486. doi: 10.21037/tau-23-106. Epub 2023 Mar 24.
6
Iliac vein compression syndrome caused by a large bladder diverticulum: Case report and literature review.巨大膀胱憩室致髂静脉压迫综合征 1 例报告并文献复习
J Int Med Res. 2022 Sep;50(9):3000605221123670. doi: 10.1177/03000605221123670.
7
Associated Factors for Prostate Enlargement in Chinese Adult Men Aged <40 Receiving Checkups.中国 40 岁以下成年男性前列腺增大的相关因素。
Int J Clin Pract. 2022 Aug 11;2022:4792451. doi: 10.1155/2022/4792451. eCollection 2022.
8
MicroRNAs from urinary exosomes as alternative biomarkers in the differentiation of benign and malignant prostate diseases.尿外泌体中的微小RNA作为鉴别前列腺良恶性疾病的替代生物标志物
J Circ Biomark. 2022 Feb 10;11:5-13. doi: 10.33393/jcb.2022.2317. eCollection 2022 Jan-Dec.
9
Thulium laser enucleation of prostate versus laparoscopic trans-vesical simple prostatectomy in the treatment of large benign prostatic hyperplasia: head-to-head comparison.钬激光前列腺剜除术与经膀胱腹腔镜单纯前列腺切除术治疗大体积良性前列腺增生的头对头比较。
Int Braz J Urol. 2022 Mar-Apr;48(2):328-335. doi: 10.1590/S1677-5538.IBJU.2021.0726.
10
The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study.基于 Phenolmicin P3 和 Bosexil(米塔拉唑®)的栓剂在控制行铥激光前列腺剜除术患者刺激性症状中的疗效:一项单中心、随机、对照、开放标签、III 期研究。
BMC Urol. 2022 Feb 12;22(1):19. doi: 10.1186/s12894-022-00974-0.